These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23537059)

  • 1. Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-α antagonists and rituximab therapy?
    Lis-Święty A; Brzezińska-Wcisło L; Widuchowska M; Kucharz E
    Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):443-6. PubMed ID: 23537059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced lupus erythematosus.
    Vedove CD; Del Giglio M; Schena D; Girolomoni G
    Arch Dermatol Res; 2009 Jan; 301(1):99-105. PubMed ID: 18797892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced lupus: an update on its dermatologic aspects.
    Marzano AV; Vezzoli P; Crosti C
    Lupus; 2009 Oct; 18(11):935-40. PubMed ID: 19762393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced lupus erythematosus.
    Marzano AV; Tavecchio S; Menicanti C; Crosti C
    G Ital Dermatol Venereol; 2014 Jun; 149(3):301-9. PubMed ID: 24819757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
    Lieberman MR; Liebman TN; Alapati U; Khachemoune A
    Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature.
    Lorentz K; Booken N; Goerdt S; Goebeler M
    J Dtsch Dermatol Ges; 2008 Oct; 6(10):823-7, 823-8. PubMed ID: 18564209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart.
    Marzano AV; Lazzari R; Polloni I; Crosti C; Fabbri P; Cugno M
    Br J Dermatol; 2011 Aug; 165(2):335-41. PubMed ID: 21564069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab.
    Diaz JC; Vallejo S; Cañas CA
    Rheumatol Int; 2012 Oct; 32(10):3315-7. PubMed ID: 21881980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab-exacerbated subacute cutaneous lupus erythematosus.
    Wilkerson E; Hazey MA; Bahrami S; Callen JP
    Arch Dermatol; 2012 Oct; 148(10):1186-90. PubMed ID: 23069957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terbinafine-induced subacute cutaneous lupus erythematosus.
    Bonsmann G; Schiller M; Luger TA; Ständer S
    J Am Acad Dermatol; 2001 Jun; 44(6):925-31. PubMed ID: 11369902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis.
    Brunasso AM; Aberer W; Massone C
    Lupus; 2014 Feb; 23(2):201-3. PubMed ID: 24356614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acebutolol-induced subacute cutaneous lupus erythematosus.
    Fenniche S; Dhaoui A; Ammar FB; Benmously R; Marrak H; Mokhtar I
    Skin Pharmacol Physiol; 2005; 18(5):230-3. PubMed ID: 16015021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.
    Suess A; Sticherling M
    Int J Dermatol; 2008 Jan; 47(1):83-6. PubMed ID: 18173611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of drug-induced subacute cutaneous lupus erythematosus.
    Lowe GC; Henderson CL; Grau RH; Hansen CB; Sontheimer RD
    Br J Dermatol; 2011 Mar; 164(3):465-72. PubMed ID: 21039412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced subacute cutaneous lupus erythematosus related to doxycycline.
    Miller KK; Chu J; Patel R; Kamino H
    Dermatol Online J; 2011 Oct; 17(10):3. PubMed ID: 22031629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.